UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 113

Sortiert nach

Lean Six Sigma innovative safety performance management

Injury prevention, 2010-09, Vol.16 (Suppl 1), p.A16-A16

Furst, P G

2010

Link zum Volltext

Verfügbarkeit prüfen

Reinventing the organisation to effectively manage safety performance

Injury prevention, 2010-09, Vol.16 (Suppl 1), p.A15-A15

Furst, P G

2010

Link zum Volltext

Verfügbarkeit prüfen

Safety strategies and the balanced score card technique

Injury prevention, 2010-09, Vol.16 (Suppl 1), p.A15-A16

Furst, P G

2010

Link zum Volltext

Verfügbarkeit prüfen

The unwritten organisational rules of engagement

Injury prevention, 2010-09, Vol.16 (Suppl 1), p.A16-A16

Furst, P G

2010

Link zum Volltext

Verfügbarkeit prüfen

Aligning the organisation to effectively manage risk

Injury prevention, 2010-09, Vol.16 (Suppl 1), p.A16-A17

Furst, P G

2010

Link zum Volltext

Verfügbarkeit prüfen

Safety excellence by design (achieving stellar performance)

Injury prevention, 2010-09, Vol.16 (Suppl 1), p.A16-A16

Furst, P G

2010

Link zum Volltext

Verfügbarkeit prüfen

Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial

Annals of the rheumatic diseases, 2011-01, Vol.70 (1), p.32-38

2011

Link zum Volltext

Verfügbarkeit prüfen

Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts

Annals of the rheumatic diseases, 2019-01, Vol.78 (1), p.122

2019

Link zum Volltext

Verfügbarkeit prüfen

2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative

Annals of the rheumatic diseases, 2013-11, Vol.72 (11), p.1747-1755

2013

Link zum Volltext

Verfügbarkeit prüfen

Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period

Annals of the rheumatic diseases, 2015-01, Vol.74 (1), p.19-26

2015

Link zum Volltext

Verfügbarkeit prüfen

Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients

Annals of the rheumatic diseases, 2013-09, Vol.72 (9), p.1496-1502

2013

Link zum Volltext

Verfügbarkeit prüfen

Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study

Annals of the rheumatic diseases, 2017-01, Vol.76 (1), p.96

2017

Link zum Volltext

Verfügbarkeit prüfen

Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management

Annals of the rheumatic diseases, 2020-06, Vol.79 (6), p.724

2020

Link zum Volltext

Verfügbarkeit prüfen

Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group

Annals of the rheumatic diseases, 2011-03, Vol.70 (3), p.476-481

2011

Link zum Volltext

Verfügbarkeit prüfen

Infliximab in active early rheumatoid arthritis

Annals of the rheumatic diseases, 2004-02, Vol.63 (2), p.149-155

2004

Link zum Volltext

Verfügbarkeit prüfen

Morphological characterisation of Crohn’s disease fistulae

Gut, 2004-09, Vol.53 (9), p.1314-1321

2004

Link zum Volltext

Verfügbarkeit prüfen

EP1168 The influence of obesity on tumor recurrence in vulvar cancer patients

International journal of gynecological cancer, 2019-11, Vol.29 (Suppl 4), p.A605-A605

2019

Link zum Volltext

Verfügbarkeit prüfen

Updated consensus statement on biological agents, specifically tumour necrosis factor α (TNFα) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005

Annals of the rheumatic diseases, 2005-11, Vol.64 (suppl 4), p.iv2-iv14

2005

Link zum Volltext

Verfügbarkeit prüfen

EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR)

Annals of the rheumatic diseases, 2009-05, Vol.68 (5), p.620-628

2009

Link zum Volltext

Verfügbarkeit prüfen

Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis

Annals of the rheumatic diseases, 2007-12, Vol.66 (12), p.1641-1647

2007

Link zum Volltext

Verfügbarkeit prüfen

Live well, die well – an international cohort study on experiences, concerns and preferences of patients in the last phase of life: the research protocol of the iLIVE study

BMJ open, 2022-08, Vol.12 (8), p.e057229

2022

Link zum Volltext

Verfügbarkeit prüfen

A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis

Annals of the rheumatic diseases, 2005-01, Vol.64 (1), p.64-69

2005

Link zum Volltext

Verfügbarkeit prüfen

Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database

Annals of the rheumatic diseases, 2021-02, Vol.80 (2), p.219

2021

Link zum Volltext

Verfügbarkeit prüfen

Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis

Annals of the rheumatic diseases, 2016-02, Vol.75 (2), p.374-381

2016

Link zum Volltext

Verfügbarkeit prüfen

Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk test

Annals of the rheumatic diseases, 2007-02, Vol.66 (2), p.169-173

2007

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 113

Suche als RSS-Feed

Aktive Filter

KollektionBMJ journals single titles

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(113)
Mit Volltextzugriff
(105)

Publikationsform

Artikel
(111)
Tagungsberichte
(2)

Sprache

Englisch
(113)
Japanisch
(13)
Russisch
(1)

Erscheinungsjahr

n.n

Thema

Humans
(52)
Life Sciences & Biomedicine
(52)
Science & Technology
(52)
Rheumatology
(48)
Female
(26)
Male
(26)
Biological And Medical Sciences
(24)
Medical Sciences
(24)
Patients
(24)
Middle Aged
(23)
Adult
(22)
Rheumatoid Arthritis
(22)
Antirheumatic Agents - Therapeutic Use
(21)
Studies
(20)
Diseases Of The Osteoarticular System
(18)
Arthritis, Rheumatoid - Drug Therapy
(16)
Treatment Outcome
(16)
Tumor Necrosis Factor-Tnf
(16)
Scleroderma
(15)
Disease
(14)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

BMJ Journals
(113)
Journals@Ovid Ovid Full Text
(107)
EZB Electronic Journals Library
(105)
BMJ Journals Archiv - DFG Nationallizenzen
(100)
MEDLINE
(52)
Publisher website
(4)
Sage Journals
(3)
Wiley-Blackwell subscription journals
(2)
JSTOR
(1)
Ingenta
(1)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Lean Six Sigma innovative safety performance management

Reinventing the organisation to effectively manage safety performance

Safety strategies and the balanced score card technique

The unwritten organisational rules of engagement

Aligning the organisation to effectively manage risk

Safety excellence by design (achieving stellar performance)

Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial

Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts

2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative

Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period

Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients

Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study

Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management

Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group

Infliximab in active early rheumatoid arthritis

Morphological characterisation of Crohn’s disease fistulae

EP1168 The influence of obesity on tumor recurrence in vulvar cancer patients

Updated consensus statement on biological agents, specifically tumour necrosis factor α (TNFα) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005

EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR)

Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis

Live well, die well – an international cohort study on experiences, concerns and preferences of patients in the last phase of life: the research protocol of the iLIVE study

A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis

Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database

Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis

Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk test

Aktive Filter

Suchergebnisse filtern